α-glucosidase inhibitors
 
acarbose
miglitol

Mechanism

inhibit α-glucosidases in intestinal brush border
delayed sugar hydrolysis
delayed glucose absorption
↓ postprandial hyperglycemia
↓ insulin demand

Clinical use

type II DM
as monotherapy or in combination with other agents

Hydromorphone

• About 8-10 times more potent than morphine when given intravenously.
• Slightly shorter duration of action.
• More soluble than morphine, thus higher concentrations may be injected if necessary.
• Better oral/parenteral absorption ratio than morphine, but not as good as codeine or oxycodone.

• It is used for the treatment of moderate to severe pain

Cephalosporins

Produced semisynthetically by chemical attachment of side chains to 7-aminocephalosporanic acid. Same mode of action , same resistance mech. 
But tend to be more resistant than penicillins to certain beta –lactamases .

GENERATION BASED ON :
-- BACTERIAL SUSCEPTIBILITY PATTERNS
-- RESISTANCE TO BETA –LACTAMASES
--NOT EFFECTIVE AGAINST -MRSA , L. MONOCYTOGENES , C. DIFFICLE , ENTEROCOCCI

First Generation 

Parentral

- CEPHALOTHIN
- CEFAZOLIN

Oral

- CEPHALEXIN
- CEPHRADINE
- CEFADROXIL

Second Generation

Parentral

CEFUROXIME
CEFOXITIN

Oral

CEFACLOR
CEFUROXIME AXETIL

Third Generation

Parentral

CEFOTAXIME 
CEFTIZOXIME
CEFTRIAXONE 
CEFTAZIDIME
CEFOPERAZONE

Oral 

CEFIXIME 
CEFPODOXIME
CEFDINIR 
CEFTIBUTEN

Fourth Generation

Parentral

CEFEPIME
CEFPIROME

Methods of general anesthesia

CIRCLE SYSTEM

*HIGH-FLOW

FRESH GAS FLOW > 3 l/min.

*LOW-FLOW

FGF ok. 1l/min.

*MINIMAL-FLOW

FGF ok. 0,5 l/min.

Oxycodone  
About equal potency to morphine. Very effective orally.

It is combined with aspirin or acetaminophen for the treatment of moderate pain and is available orally

Oxycodone is a semisynthetic compound derived from thebaine, with agonist activity primarily at mu receptors.

Heparin:

• Inhibits blood coagulation by forming complexes with an α2-globulin (Antithrombin III) and each of the activated proteases of the coagulation cascade (Kallikrein, XIIa, XIa, IXa, Xa, and Thrombin). After formation of the heparin-ATIII-coagulation factor, heparin is released and becomes available again to bind to free ATIII.
• Blocks conversion of Prothrombin to Thrombin and thus inhibits the synthesis of Fibrin from Fibrinogen.
• Inhibits platelet function and increases vascular permeability. May induce moderate to severe thrombocytopenia.
• Is prescribed on a “unit” basis.
• Heparin is not effective after oral administration and is generally administered by intravenous or subcutaneous injection. Intramuscular injections should be avoided.
• Heparin does not cross the placenta and does not pass into the maternal milk.
• is contraindicated in any situation where active bleeding must be avoided.

Ulcerative lesions, intracranial hemorrhage, etc.

Overdosage:

• Simple withdrawal.

• Protamine sulfate: Highly basic peptide that binds heparin and thus neutralizes its effects.